Total number of additional common shares of an entity that have been sold or granted to shareholders.

No definition available.

Name:	nnvc_AdditionalCommonStockSharesIssued
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of additional nonredeemable preferred shares issued to shareholders.

+ References

No definition available.

+ Details

Name:	nnvc_AdditionalPreferredStockSharesIssued
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- References

No definition available.

+ Details

Name:	nnvc_CommitmentsAndContingenciesLineItems
Namespace Prefix:	nnvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of Consulting services payments.

+ References

No definition available.

+ Details

Name:	nnvc_ConsultingServicesPayments
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Date the employment agreement was made.

+ References

No definition available.

+ Details

Name:	nnvc_EmploymentAgreementTerm
Namespace Prefix:	nnvc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents the certain amount of estimated salary increase in their base.

+ References

No definition available.

+ Details

Name:	nnvc_IncreaseInBaseSalary
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The compensation expense recognized during the period pertaining to the deferred compensation arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363

+ Details

Name:	us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

+ Details

Name:	us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares issued under share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of non-vested options forfeited.

+ References

No definition available.

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of options vested.

+ References

No definition available.

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=nnvc_YearOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=nnvc_YearTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=nnvc_YearThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=nnvc_ChiefScientificOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_PresidentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_VicePresidentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=nnvc_MrTaraporewalaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($)						3 Months Ended		6 Months Ended
Commitments and Contingencies (Details) - USD ($)	Nov. 01, 2019	Jul. 11, 2018	Jan. 01, 2015	May 30, 2013	Mar. 03, 2010	Dec. 31, 2019	Sep. 30, 2018	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies [Line Items]
Common stock, shares issued						3,870,572		3,870,572	3,844,921
Deferred Compensation Arrangement with Individual, Compensation Expense								$ 400,000
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance						26,250		26,250
Employment Agreement Term								3 years
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								8,750
TheraCour
Commitments and Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues	75,000
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued						366,488		366,488	255,714
Stock Issued During Period, Shares, New Issues	75,000
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								2 years
Employment Agreement Term							3 years
Chief Executive Officer [Member] \| Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense								$ 360,000
Chief Executive Officer [Member] \| Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense								15,000
Chief Executive Officer [Member] \| Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense								5,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued					1,786
Additional Common Stock Shares Issued					1,786
Increase In Base Salary					$ 150,000
Employment Agreement Term					4 years
President [Member] \| Series A Preferred stock
Commitments and Contingencies [Line Items]
Share-based Compensation						$ 47,260		$ 94,520
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		26,250
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued					1,786
Additional Common Stock Shares Issued					1,786
Preferred stock, shares issued					1,340
Additional Preferred Stock Shares Issued					1,340
Increase In Base Salary					$ 150,000
Employment Agreement Term					4 years
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary			$ 10,800	$ 9,000
Employment Agreement Term				3 years
Chief Financial Officer [Member] \| Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued				129
Mr Taraporewala [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								2 years
Consulting Services Payments						$ 3,000		$ 3,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares								10,000